The objective of this study was to cross-culturally adapt and validate the Incontinence-Specifi c Quality of Life instrument (I-QOL) for Brazilian women with urinary incontinence. METHODS: The I-QOL is a scale devised to assess quality of life impairment due to urinary incontinence. This questionnaire has been used in numerous studies to evaluate the consequences of the disease in daily life or the effects of different treatments. Seventy patients with urinary incontinence, were enrolled from the outpatient clinic of the Uroginecology and Vaginal Surgery Section of the Gynecology Department of the Federal University of São Paulo (UNIFESP). Initially, we translated the I-QOL into Brazilian Portuguese language following international methodological recommendations. Due to language and cultural differences we performed cultural, structural, conceptual, and semantic adaptation on the I-QOL, in order that patients were able to fully understand the questions. All patients answered I-QOL twice on the same day with an interval of 30 minutes, applied by two different interviewers. Also the Kingxs Health Questionnaire (KHQ), already translated and validated to Brazilian Portuguese was applied to the patients. After 7 to 15 days, by phone interview, only I-QOL was applied again. Reliability (intra and inter observer internal consistency), construct and discriminative validity were tested. RESULTS: Several cultural adaptations were necessary until we reached the fi nal version. The intraobserver internal consistence (alpha of Cronbachxs) of the several dimensions varied from moderate to high (0.77-0.93), and the inter observer internal consistence varied from 0.65 to 0.88. Moderate to strong correlation was detected among the I-QOL dominions and the validated Brazilian Portuguese version of KHQ. CONCLUSIONS: I-QOL was adapted to the Portuguese language and to the Brazilian culture, showing good reliability and validity. This questionnaire is now being evaluated in clinical trials on new therapeutic strategies for urinary incontinence in Brazil. Interviews with people with CKD (n 12) provided detailed qualitative data regarding patients' HRQL. Qualitative analysis identifi ed how HRQL varied by three levels of anemia (mild 12.5 g/dL; moderate 12.5-10.5 g/dL, and severe 10.5 g/dL; set according to the recent National Institute of Clinical Excellence [NICE] clinical guidelines on CKD) and three states of CKD (pre-dialysis, peritoneal dialysis, and hemodialysis). Vignette descriptions of HRQL were developed for each state, and patients and clinicians assessed content validity. Vignettes were rated by 100 members of the general public in the UK using the time trade-off interview to estimate health state utilities. RESULTS: The qualitative data produced very detailed vignettes that were determined by patients and clinicians to have good content validity. Utilities varied for pre-dialysis (0.787-0.431), peritoneal dialysis (0.725-0.351), and hemodialysis (0.629-0.331) between mild to severe levels of anemia, respectively. CONCLUSIONS: The vignette descriptions were based upon qualitative data and validated through content validation interviews with clinicians and patients. To our knowledge, this is the fi rst study in which vignettes have been developed entirely based on qualitative data from patient interviews. This is a useful method for estimating utilities when no data from generic instruments are available.
PUK17 THE FDA DRAFT GUIDANCE ON PATIENT-REPORTED OUTCOMES CAN BE USED TO IMPROVE THE ESTIMATION OF UTILITIES. A CASE STUDY IN CHRONIC KIDNEY DISEASE
Lloyd A y 1 , Falconer S 1 , Halton J 2 , Pandya B 3 , Pang F 2 1 Oxford Outcomes Ltd, Oxford, UK, 2 Takeda Global Research and Development (Europe), London, UK, 3 Takeda Pharmaceuticals North America, Inc, Deerfi eld, IL, USA OBJECTIVES: The FDA draft guidance on patient-reported outcomes (PROs) outlines methods for developing disease-specifi c PROs. The aim of the present study was to develop and validate vignette descriptions of health-related quality of life (HRQL) in people who have anemia associated with chronic kidney disease (CKD) by adapting the FDA methods for developing PROs to derive health state utilities. METHODS: Interviews with people with CKD (n 12) provided detailed qualitative data regarding patients' HRQL. Qualitative analysis identifi ed how HRQL varied by three levels of anemia (mild 12.5 g/dL; moderate 12.5-10.5 g/dL, and severe 10.5 g/dL; set according to the recent National Institute of Clinical Excellence [NICE] clinical guidelines on CKD) and three states of CKD (pre-dialysis, peritoneal dialysis, and hemodialysis). Vignette descriptions of HRQL were developed for each state, and patients and clinicians assessed content validity. Vignettes were rated by 100 members of the general public in the UK using the time trade-off interview to estimate health state utilities. RESULTS: The qualitative data produced very detailed vignettes that were determined by patients and clinicians to have good content validity. Utilities varied for pre-dialysis (0.787-0.431), peritoneal dialysis (0.725-0.351), and hemodialysis (0.629-0.331) between mild to severe levels of anemia, respectively. CONCLUSIONS: The vignette descriptions were based upon qualitative data and validated through content validation interviews with clinicians and patients. To our knowledge, this is the fi rst study in which vignettes have been developed entirely based on qualitative data from patient interviews. This is a useful method for estimating utilities when no data from generic instruments are available.
PUK18 PATIENT PREFERENCE FOR TAMSULOSIN OCAS (ORAL CONTROLLED ABSORPTION SYSTEM) OVER TAMSULOSIN MODIFIED RELEASE CAPSULES
Khastgir J 1 , Odeyemi I 2 , Sidhu M 2 1 Morriston Hospital ABM University Hospitals Trust, Swansea, Wales, UK, 2 Astellas Pharma Europe Ltd, Staines, Middlesex, UK OBJECTIVES: Tamsulosin Ocas (oral controlled absorption system) is an improved formulation of tamsulosin modifi ed release (MR) capsules, providing a smoother 24h plasma concentration profi le, improved Cmax/C24h ratio, and independence from oral food intake [1] . The formulations are similarly effective, but tamsulosin Ocas is associated with a lower incidence of orthostatic hypotension and abnormal ejaculation [2, 3] . Our objective was to determine if patients preferred tamsulosin Ocas over tamsulosin MR. METHODS: Discrete Choice Analysis based on 12 hypothetical paired scenarios was used to compare patient preferences in 50 men aged 45 years with LUTS/BPH. Each scenario included convenience of administration with/without food, frequency of orthostatic hypotension, ejaculatory dysfunction, and out-of-pocket expenses; one mandatory pair tested for irrationality. Disease severity and healthrelated quality of life were assessed by IPSS and EuroQol EQ-5D. RESULTS: 56% of the trial population had moderate and 26% had severe symptoms on IPSS scores; mean EQ-5D was 0.78. Five respondents with irrational responses were excluded. Respondents were signifi cantly more likely to prefer tamsulosin Ocas over MR overall (OR 19.45; 95% CI 6.27, 60.39; p 0.001 To assess the effi cacy of solifenacin on patient-reported outcomes and diary-documented Overactive Bladder (OAB) symptoms. METHODS: 768 patients with OAB for 3 months were randomized to fl exibly dosed solifenacin (5-10 mg) or placebo for 12 weeks; dose modifi cations were permitted at Weeks 4 and 8. At baseline and Week 12, patients completed the Overactive Bladder Questionnaire (OAB-q), comprised of a Symptom Bother scale (primary endpoint) and Health-Related Quality of Life (HRQL) scale with 4 domains (Coping, Concern, Sleep, Social Interactions), Work Productivity and Activity Impairment (WPAI) Questionnaire, which assesses the impact of bladder-related problems on absenteeism (work time missed), presenteeism (impairment at work), work productivity loss, and activity impairment, a 100-mm Treatment Satisfaction Visual Analog Scale (TS-VAS; higher values indicate greater satisfaction) and 3-day bladder diaries for recording episodes of urgency, incontinence, micturition frequency, and nocturia. RESULTS: By study end, solifenacin versus placebo signifi cantly improved mean OAB-q Symptom Bother ( 29.9 vs 20.4, P 0.0001), HRQL total (25.3 vs 16.7, P 0.0001) and all domain scores (all Ps 0.0001). WPAI results revealed that solifenacin versus placebo signifi cantly improved presenteeism ( 14.6% vs 8.7%), work productivity loss ( 12.9% vs 8.2%), and activity impairment ( 18.1% vs 14.7%; all Ps 0.01), but not absenteeism ( 0.5 vs 0.1; P 0.50), likely because baseline levels were low (1.1% vs. 1.4%). On the TS-VAS, mean change from baseline was signifi cantly larger among solifenacin versus placebo patients (38.2 vs 18.4; P 0.0001). Solifenacin vs placebo also signifi cantly reduced mean daily episodes of urgency ( 3.05 vs 1.84; P 0.0001), incontinence ( 1.85 vs 1.24; P 0.003), and frequency ( 2.23 vs 1.36; P 0.0001), but not nocturia ( 0.63 vs 0.48; P 0.34). CONCLUSIONS: Flexibly dosed solifenacin signifi cantly improved OAB symptom bother, HRQL, work productivity, and OAB symptoms. Patients who received solifenacin versus placebo also showed a signifi cantly greater increase in overall treatment satisfaction.
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PUK20 PROFILING COMMON CO-MORBIDITIES AND MEDICATIONS PRESCRIBED AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE
Rasu R 1 , Karve S 2 , Abercrombie M 3 , Balkrishnan R 2 1 University of Missouri-Kansas City, Kansas City, MO, USA, 2 Ohio State University, Columbus, OH, USA, 3 University of Missouri Kansas City, Kansas City, MO, USA OBJECTIVES: Patients with chronic kidney disease (CKD) often have fi ve to six other co-morbid conditions thus requiring extensive therapeutic treatment. Therefore, the objective of this study was to examine the most common co-morbid conditions and medications prescribed among patients with CKD, using a recent national population based ambulatory care survey. METHODS: This study utilized the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) data from 2002 through 2005. The NAMCS and NHAMCS are national probability surveys of visits to offi ce-based physicians and ambulatory services in hospital outpatient and emergency departments. CKD-related visits were identifi ed using diagnosis codes 572.4, (580) (581) (582) (583) (584) (585) (586) (587) (588) 591, 593.9, 572.4, 753.1, 753.3, 753.2, V18.6, 794.4) or prescription for CKD specifi c medications (brand and generic drug codes: calcium acetate,sevelamer,lanthanum carbonate,cinacalcet). Frequency analysis of the CKD visits by setting and demographic characteristics was performed. Similarly, frequency analysis was performed to identify the most common co-morbid diagnosis and medications prescribed among CKD patients. National estimates on visits were estimated using patient visits weights provided in the NAMCS and NHAMCS. RESULTS: In, 2005 there were 9.7million visits related to CKD, 8.1 million physician offi ce visits, 0.9 million emergency department, and 0.7 million outpatient hospital department visits, representing a 140% increase compared to 7.1 million visits in 2002. The most common co-morbid conditions among CKD patients were essential hypertension (22.3%), diabetes mellitus (17.5%),
